Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Northbrook, Illinois Clinical Trials

A listing of Northbrook, Illinois clinical trials actively recruiting patient volunteers.

RESULTS

Found (72) clinical trials

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

Primary Objective: To determine the irRECIST* response rate of pembrolizumab with ipilimumab following initial progression or stable disease to anti-PD1/L1 antibody (or combination not containing anti-CTLA4) in subjects with advanced melanoma. Secondary Objective To summarize the progression-free survival (RECIST v1.1 and irRC) of the combination following prior treatment with anti-PD1/L1 ...

Phase

7.83 miles

Learn More »

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

PRIMARY OBJECTIVES: I. To determine if dose-escalated and -intensified photon IMRT or proton beam therapy (using a dose-per-fraction escalation with simultaneous integrated boost) with concomitant and adjuvant temozolomide improves overall survival, as compared to standard-dose photon irradiation with concomitant and adjuvant temozolomide. SECONDARY OBJECTIVES: I. To indirectly compare dose-escalated and ...

Phase

7.83 miles

Learn More »

Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer

This is an open-label, multi-center, randomized, Phase 2 study designed to compare the efficacy and safety of AM0010 in combination with Pembrolizumab versus Pembrolizumab alone in patients with stage IV / metastatic wild type Non-Small Cell Lung Cancer and tumors with high expression of PD-L1 (> 50%)

Phase

7.87 miles

Learn More »

Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer

PRIMARY OBJECTIVES: I. To describe the progression-free survival (PFS) of stereotactic body radiation therapy (SBRT) + pembrolizumab (MK-3475) compared to MK-3475 alone in advanced/metastatic merkel cell carcinoma (MCC) patients. SECONDARY OBJECTIVES: I. To describe the PFS of SBRT + MK-3475 compared to MK-3475 alone across Response Evaluation Criteria in Solid ...

Phase

7.95 miles

Learn More »

Study to Compare Oral PF-06651600 PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.

Phase

8.3 miles

Learn More »

The purpose of this study is to see if GS-9073 can benefit people with CLL. This study will also investigate the safety of GS-9973 and how weel the drug is tolerated.

Phase

8.3 miles

Learn More »

A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer

Both investigator determined and independent blinded central review will be used for determining outcomes.

Phase

8.3 miles

Learn More »

A Study of MTIG7192A in Combination With Atezolizumab in Chemotherapy-Na ve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study will evaluate the safety and efficacy of MTIG7192A plus Atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation.

Phase

8.3 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

The study consists of four phases: 4-week Screening Phase 24-week placebo-controlled phase Subjects will receive either 0.45 mg QD, 0.3 mg QD, 0.15 mg QD or placebo for the first 24 weeks of treatment. 28-week active treatment phase At Week 24, all subjects on placebo will be re-randomized to active ...

Phase

8.48 miles

Learn More »

Intra-articular Platelet-Rich Plasma Compared With Viscosupplementation in the Treatment of Knee Osteoarthritis

This is a prospective, randomized, single-blind, comparative clinical trial with an allocation ratio of 1:1. The primary endpoint is the MRI-based cartilage thickness measurement. The secondary endpoint is the KOOS total score. There are 2 arms: PRP treatment and HA treatment. Due to the treatment procedure, the study will not ...

Phase

8.48 miles

Learn More »